BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Sabre//Sabre VObject 4.5.8//EN
CALSCALE:GREGORIAN
BEGIN:VTIMEZONE
TZID:Europe/Zurich
X-LIC-LOCATION:Europe/Zurich
TZURL:http://tzurl.org/zoneinfo/Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:19810329T020000
RRULE:FREQ=YEARLY;BYMONTH=3;BYDAY=-1SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:19961027T030000
RRULE:FREQ=YEARLY;BYMONTH=10;BYDAY=-1SU
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
UID:news499@dbe.unibas.ch
DTSTAMP;TZID=Europe/Zurich:20260428T113904
DTSTART;TZID=Europe/Zurich:20260528T163000
SUMMARY:From Genes to Joints: Using Multi-Omics to Dissect Musculoskeletal 
 Disease
DESCRIPTION:AbstractMusculoskeletal diseases such as arthritis and interver
 tebral disc degeneration represent the leading cause for disability and ch
 ronic pain worldwide. Without effective treatments addressing the root cau
 se of these conditions\, more and more individuals suffer from musculoskel
 etal ailments as the population continues to age. Multi-omic technologies 
 are revolutionizing the discovery of disease mechanisms and have become cr
 itical in the development of new therapeutic strategies. With a strong bio
 engineering focus\, Prof. März will summarize the use of multi-omics to u
 nderstand the pathobiology of arthritis\, emphasizing its application to i
 dentify new targets for disease-modifying treatments.\\r\\nBiosketchProf. 
 Dr. Tristan März is the Associate Professor of Musculoskeletal Bioenginee
 ring at ETH Zürich\, where he leads the Musculoskeletal Bioengineering La
 boratory within the Department of Health Sciences and Technology at the In
 stitute for Biomechanics. His research is focused on the molecular mechani
 sms of arthritis\, encompassing studies of synovial inflammation and fibro
 sis to cartilage degeneration and pain signaling. He employs advanced imag
 ing\, multi-omic profiling\, mechanobiological models\, and emerging AI-dr
 iven analytical approaches to uncover actionable therapeutic target. Befor
 e joining ETH Zürich in 2025\, he led an interdisciplinary research group
  as Associate Professor of Orthopaedic Surgery\, Biomedical Engineering\, 
 and Rheumatology at the University of Michigan. His goal is to foster a dy
 namic environment in which young scientists can contribute to ambitious\, 
 forward-looking bioengineering projects so that effective treatments for m
 usculoskeletal diseases can finally be developed.
X-ALT-DESC:<p><strong>Abstract</strong><br />Musculoskeletal diseases such 
 as arthritis and intervertebral disc degeneration represent the leading ca
 use for disability and chronic pain worldwide. Without effective treatment
 s addressing the root cause of these conditions\, more and more individual
 s suffer from musculoskeletal ailments as the population continues to age.
  Multi-omic technologies are revolutionizing the discovery of disease mech
 anisms and have become critical in the development of new therapeutic stra
 tegies. With a strong bioengineering focus\, Prof. März will summarize th
 e use of multi-omics to understand the pathobiology of arthritis\, emphasi
 zing its application to identify new targets for disease-modifying treatme
 nts.</p>\n<p><strong>Biosketch</strong><br />Prof. Dr. Tristan März is th
 e Associate Professor of Musculoskeletal Bioengineering at ETH Zürich\, w
 here he leads the Musculoskeletal Bioengineering Laboratory within the Dep
 artment of Health Sciences and Technology at the Institute for Biomechanic
 s. His research is focused on the molecular mechanisms of arthritis\, enco
 mpassing studies of synovial inflammation and fibrosis to cartilage degene
 ration and pain signaling. He employs advanced imaging\, multi-omic profil
 ing\, mechanobiological models\, and emerging AI-driven analytical approac
 hes to uncover actionable therapeutic target. Before joining ETH Zürich i
 n 2025\, he led an interdisciplinary research group as Associate Professor
  of Orthopaedic Surgery\, Biomedical Engineering\, and Rheumatology at the
  University of Michigan. His goal is to foster a dynamic environment in wh
 ich young scientists can contribute to ambitious\, forward-looking bioengi
 neering projects so that effective treatments for musculoskeletal diseases
  can finally be developed.</p>
DTEND;TZID=Europe/Zurich:20260528T173000
END:VEVENT
END:VCALENDAR